Third Quarter 2026 Earnings Conference Call - BIOVENTUS INC

Explicit Guidance:

• Full-Year 2026 Revenue: Reaffirmed range of $590 million to $595 million, reflecting a mid-single-digit growth rate in Q4 and sequential acceleration from Q3.
• Full-Year 2026 Adjusted EPS: Reaffirmed guidance of $0.75 to $0.79 per diluted share.
• Full-Year 2026 Cash Flow: Adjusted cash from operations guidance raised to $89 million (previously $84 million), excluding the cash flow impact of the strategic alternatives review.
• Q4 2026 Revenue: Expects mid-single-digit growth, driven by sequential acceleration.
• Q4 2026 Adjusted EBITDA Margin: Expects to remain above prior year levels (prior year Q3: 19.3%), maintaining the full-year trend.
• FY2026 Net Debt: Expect to remain below $200 million (current: < $200 million).
• FY2026 Net Leverage Ratio: Expect to be below 1.5 times by year-end.
• Restorative Therapies (Exygen): Expects low single-digit growth for the full year, factoring into Q4 guidance.

Business-Segment Outlook:

• Growth Drivers (2027 & Beyond):
  • PNS (Pain Treatments): Expects revenue growth to "ramp strongly" throughout 2027, supported by trial-to-permanent conversion rates exceeding plans and a >50% QoQ increase in trained physicians.
  • PRP: Sequential growth in capital placements and meaningful ramp-up in disposable reorders expected to continue; disposables revenue now exceeds capital placement revenue. Exclusive rights for sports medicine accounts broaden the addressable market.
  • Ultrasonics: Expects very strong growth in Q4 2026 and further acceleration in 2027 driven by marketing, surgeon training, and new account wins; disposables showing positive, continuous, sequential growth.
  • International: Expects >20% growth in Q4 2026 and "continued excellent growth in 2027," building on 16% Q3 acceleration and 18% constant currency growth.
• Surgical Solutions (BGS): Expects sequential acceleration in Q4 2026 following late-Q3 actions to address competitive dynamics in the synthetic space and the ramp-up of new distributors; headwinds viewed as transitory.
• Restorative Therapies: Expects growth rate to improve in Q4 2026 as sales force vacancies are filled; long-term growth expected to remain in the low-to-mid single-digit range.
• PNS Scale: Expects to scale the PNS business to over $100 million in the coming years.

Market and Competitive Outlook:

• Demand Trends: Clinicians gaining experience with Talisman (PNS) validates technology; strong traction in IDN (Integrated Delivery Network) RFPs based on clinical and economic value propositions.
• Pricing/Competition: Addressed competitive dynamics in the synthetic BGS market late in Q3; seeing positive results in October ahead of expectations.
• Share Shifts: PRP solutions showing potential to displace competitive offerings; Ultrasonics gaining traction with new surgeons and disposables volume.
• IDN Strategy: Gaining significant momentum with large accounts moving toward separating biologics RFPs and basing decisions on product-specific value.

Macro / Industry Outlook:

• Spine Market: Acknowledged near-term softness in spine procedural volumes but views this as a temporary headwind for BGS that does not materially impact the Ultrasonics segment.
• Interest Rates: Anticipates interest expense savings as a result of net debt reduction, enhancing earnings power and capital allocation flexibility.
• Foreign Exchange: International growth highlighted as 18% on a constant currency basis in Q3, indicating resilience to FX headwinds.

Strategic Initiatives:

• Investment Scale: Accelerated investment in growth drivers to $15 million for 2026 (up from the original $13 million guidance), with >50% allocated to P&S.
• Capital Deployment: Continued focus on debt reduction ($65M repaid YTD) to lower net debt below $200M, enhancing optionality for future capital allocation.
• Strategic Review: Ongoing evaluation of strategic options following unsolicited acquisition proposals; no timeline or outcome provided, no questions to be answered regarding details.
• Talent & Infrastructure: Continued hiring and training, including >50% growth in trained physicians for PNS and expansion of international talent teams.

Risks and Headwinds to Outlook:

• BGS Volatility: Near-term softness in spine procedures, temporary delays in distributor onboarding, and competitive dynamics in the synthetic market (viewed as transitory but caused the Q3 miss).
• Sales Force Efficiency: Exygen revenue was impacted by sales force vacancies (now filled) and execution on commercial targeting.
• Strategic Uncertainty: The ongoing strategic review creates uncertainty regarding potential M&A or restructuring timing and financial impact.
• Pricing/Volume Mix: Variability in product mix and pricing pressure in specific segments (e.g., BGS) could impact margins if not offset by growth in higher-margin lines.

Management Tone on the Future:

• Confidence Level: High conviction in the business model's ability to balance investment with profitability; described Q3 performance as "reinforcing our conviction."
• Forward View: Management expresses excitement about "ramping strongly" in 2027, citing "positive momentum" and "leading indicators" that are "tracking ahead of launch plans."
• Revisions: Confident in the revised 2026 revenue guidance ($590–$595M) despite Q3 misses, citing early Q4 traction in BGS and accelerating growth in international and pain segments.

Miscellaneous:

• Strategic Investment Efficiency: Despite higher-than-planned investments ($15M vs $13M), adjusted EBITDA margin expanded 70 bps to 20% in Q3, demonstrating P&L resilience.
• Segment Revenue Mix: Pain treatments drove 6% growth (led by HA portfolio, PRP, and PNS); International revenue contributed 16% growth.
• FY2027 Outlook: No formal numerical guidance for 2027 provided, but qualitative outlook suggests "acceleration" in revenue growth and "ramping" for key segments like PNS and Ultrasonics.